Children & Adolescents
PAS 2017: Sofosbuvir Plus Ribavirin Cures Teens with Genotype 2 or 3 Hepatitis C
- Details
- Category: Children & Adolescents
- Published on Tuesday, 16 May 2017 00:00
- Written by Liz Highleyman
A 2-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course cured all but one teen with harder-to-treat genotype 3, according to a presentation at the 2017 Pediatric Academic Societies Meeting last week in San Francisco.
EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
- Details
- Category: HCV Treatment
- Published on Friday, 21 April 2017 00:00
- Written by Liz Highleyman
Almost all children age 6 to 11 with hepatitis C who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver damage even at that young age, according to a presentation at the at the EASL International Liver Congress this week in Amsterdam.
FDA Approves Harvoni and Sovaldi for Adolescents with Hepatitis C
- Details
- Category: Approved HCV Drugs
- Published on Saturday, 08 April 2017 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) on April 7 approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents age 12 to 17 years. Sofosbuvir/ledipasvir (Harvoni) is now indicated for adolescents with HCV genotypes 1, 4, 5, or 6, while sofosbuvir (Sovaldi) plus ribavirin is approved for those with genotypes 2 or 3.
Web Design and Development by